GlobeNewswire·Nov 5, 2026, 4:17 PM ET

Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch

Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons' annual meeting, with serious infection rates reported as high as 23%.
Elutia's GLP rabbit antibacterial study for NXT-41x achieved prespecified endpoints, showing complete eradication of 8-log MRSA & 6-log E. coli challenges with no viable bacteria recovered.
Elutia secured $26 million in capital without an equity offering through the Boston Scientific holdback, SimpliDerm business sale, & an Avenue Capital loan facility.
Elutia's cardiovascular business revenue grew 20% year-over-year in Q3 2026 & 65% for the first nine months of 2026.
The company plans to submit NXT-41x to the FDA in Q4 2026 following the positive in vivo study results.
NXT-41x FDA clearance is anticipated in the first half of 2027, with a full commercial launch expected in 2028.
Q3 2026 net sales reached $1.1 million, up 20.4% from the prior year period, with an adjusted gross margin of 85.5%.
Total operating expenses for Q3 2026 were $7.6 million, driven primarily by a $1.9 million increase in research & development costs.
Elutia reported a net loss of $1.3 million for Q3 2026, compared to a $3.9 million loss in the same period of 2025.
Cash & cash equivalents stood at $29.1 million as of September 30, 2026, with sufficient funding to support operations through the anticipated NXT-41x clearance & launch.

Company: Elutia Inc.
Keywords: Nasdaq:ELUT, Elutia Inc., Elutia, Drug-Eluting, Healthcare Technology, Medical Device, Breast Reconstruction, Healthcare